Anika Therapeutics announced successful completion of the first human surgical procedure with the company’s injectable hyaluronic acid-based bone repair therapy to treat bone voids and defects caused by trauma or age-related degeneration.
The product will launch in late 3Q19 through the company’s hybrid commercial model, which pairs a small in-house business development team with strategic partners who have an orthopedic salesforce.
Anika’s therapy combines calcium phosphate bone substitute material with the company’s proprietary hyaluronic acid to enhance flow and tactile feel during delivery. It is resorbed and replaced by the growth of new bone during the healing process.
Anika Therapeutics announced successful completion of the first human surgical procedure with the company's injectable hyaluronic acid-based bone repair therapy to treat bone voids and defects caused by trauma or age-related degeneration.
The product will launch in late 3Q19 through the company's hybrid commercial model, which pairs a...
Anika Therapeutics announced successful completion of the first human surgical procedure with the company’s injectable hyaluronic acid-based bone repair therapy to treat bone voids and defects caused by trauma or age-related degeneration.
The product will launch in late 3Q19 through the company’s hybrid commercial model, which pairs a small in-house business development team with strategic partners who have an orthopedic salesforce.
Anika’s therapy combines calcium phosphate bone substitute material with the company’s proprietary hyaluronic acid to enhance flow and tactile feel during delivery. It is resorbed and replaced by the growth of new bone during the healing process.
Copy to clipboard 
